

Highly Effective Ni-Catalyzed Alkynylation of Unactivated (Hetero)arene C-H Bonds with Alkynes

Yue-Jin Liu,^a Yan-Hua Liu,^a Sheng-Yi Yan,^a and Bing-Feng Shi^{*a,b}

^aDepartment of Chemistry, Zhejiang University, Hangzhou 310027, China

^bState Key Laboratory of Bioorganic & Natural Products Chemistry, Shanghai Institute of Organic
Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

Supporting Information

Table of Contents:

1. General information	S2
2. Experimental Section	S3
2.1 Preparation of Substrates	S3
2.2 Optimization of Reaction Conditions	S7
2.3 General Procedure for the Alkynylation	S12
2.4 Gram-scale Reaction	S37
2.5 Mechanistic Investigation	S38
3. References	S39
4. Spectra	S40

1. General Information


Trimethylacetonitrile was dried by Sodium, distilled under reduced pressure and stored under nitrogen. $\text{Ni}(\text{OTf})_2$ was prepared by reported procedure.^[1] The other materials and solvents were purchased from Aladdin and other commercial suppliers and used without additional purification. NMR spectra were recorded on a Bruke Avance operating for ^1H NMR at 400 MHz, ^{13}C NMR at 100 MHz, and ^{19}F NMR at 376 MHz, using TMS as internal standard. The peaks were internally referenced to TMS (0.00 ppm) or residual undeuterated solvent signal (77.16 ppm for ^{13}C NMR). The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, b = broad. Mass spectroscopy data of the products were collected on an HRMS-TOF instrument or a low-resolution MS instrument using EI ionization.

2. Experimental Section

2.1 Preparation of Substrates


Compounds **1a-1e**, **1g-1h**, **1j-1m**, **1o**, **1q-1t**, **1a-d₅**, **4b** and **4d-4g** were known compounds.^[2, 3] Compounds **1f**, **1i**, **1n**, **1p**, **1u**, **1v** and **1ae** were prepared following typical method A or method B.^[3]

General Procedure for the Preparation of Starting Materials (Method A):




A solution of an acid (5 mmol) was refluxed in 5 mL SOCl₂ for 2h and cooled to RT. The excess of SOCl₂ was removed under vacuum to give corresponding acid chloride. The acid chloride was then re-dissolved in 5 mL dry CH₂Cl₂ and added dropwise to a 20 mL dry CH₂Cl₂ solution containing amine (5 mmol) and Et₃N (10 mmol) at 0 °C. After stirring for 6h at ambient temperature, the resulting mixture was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give the desired product.

General Procedure for the Preparation of Starting Materials (Method B):




A mixture of amine (5 mmol), 6-bromohexanoic acid (5 mmol), EDCI (5.5 mmol) and HOBT (5.5 mmol) in anhydrous DMF (20 mL) was stirred at room temperature overnight. Water was added and the mixture was extracted with diethyl ether. The combined organic layer was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give the desired product.




2-Chloro-N-(2-(pyridin-2-yl)propan-2-yl)benzamide **1f**

The title compound **1f** was prepared according to the general procedure (Method A). ^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, J = 4.0 Hz, 1H), 8.36 (br, 1H), 7.73 (td, J = 7.6, 2.0 Hz, 1H), 7.63 (dd, J = 7.6, 2.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 7.6, 1.6 Hz, 1H), 7.36 – 7.28 (m, 2H), 7.19 (ddd, J = 7.6, 4.8, 0.8 Hz, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.94, 164.34, 147.75, 137.25, 137.06, 130.99, 130.79, 129.75, 127.02, 122.04, 119.58, 57.63, 27.64; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{OCl}$ (M^+): 274.0873, found: 274.0874.



3-bromo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide **1i**


The title compound **1i** was prepared according to the general procedure (Method A). ^1H NMR (400 MHz, CDCl_3) δ 8.90 (br, 1H), 8.57 (d, J = 4.8 Hz, 1H), 8.05 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.77 (td, J = 8.0, 1.6 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.24 (dd, J = 7.6, 6.0 Hz, 1H), 1.87 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.84, 164.54, 147.71, 138.23, 137.47, 134.13, 130.49, 130.12, 125.64, 122.83, 122.18, 119.66, 56.88, 27.53.



N-(2-(pyridin-2-yl)propan-2-yl)-2-naphthamide **1l**


The title compound **1l** was prepared according to the general procedure (Method A). ^1H NMR (400 MHz, CDCl_3): δ 8.47 (ddd, J = 4.4, 2.0, 0.8 Hz, 1H), 8.39 (m, 1H), 8.34 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.88 (m, 1H), 7.78 – 7.69 (m, 2H), 7.57 – 7.45

(m, 4H), 7.20 (ddd, $J = 6.8, 5.6, 0.8$ Hz, 1H), 1.98 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 168.89, 164.42, 147.67, 137.18, 135.94, 133.77, 130.35, 130.10, 128.22, 126.86, 126.22, 125.68, 124.86, 121.94, 119.49, 57.29, 27.67; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_3$ (M^+): 289.1419, found: 289.1425.




2-chloro-N-(2-(pyridin-2-yl)propan-2-yl)nicotinamide **1n**

The title compound **1n** was prepared according to the general procedure (Method B). ^1H NMR (400 MHz, CDCl_3) δ 8.75 (br, 1H), 8.48 (ddd, $J = 6.8, 4.0, 1.6$ Hz, 2H), 8.02 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.76 (td, $J = 8.0, 1.6$ Hz, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.33 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.22 (ddd, $J = 7.6, 4.8, 0.8$ Hz, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.12, 163.90, 150.50, 147.67, 139.00, 137.41, 133.20, 122.68, 122.20, 119.54, 57.75, 27.46.




3-chloro-N-(2-(pyridin-2-yl)propan-2-yl)isonicotinamide **1p**

The title compound **1p** was prepared according to the general procedure (Method B). ^1H NMR (400 MHz, CDCl_3) δ 8.75 (br, 1H), 8.66 (d, $J = 4.0$ Hz, 1H), 8.57 (d, $J = 4.8$ Hz, 1H), 8.48 (d, $J = 4.0$ Hz, 1H), 7.76 (m, 1H), 7.54 (d, $J = 4.0$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.23 (m, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.67, 163.45, 150.46, 148.27, 147.59, 143.29, 137.49, 128.21, 123.26, 122.26, 119.52, 57.78, 27.46.




4-chloro-N-(2-(pyridin-2-yl)propan-2-yl)thiophene-2-carboxamide **1u**

The title compound **1u** was prepared according to the general procedure (Method B). ¹H NMR (400 MHz, CDCl₃) δ 8.76 (br, 1H), 8.54 (d, *J* = 4.8 Hz, 1H), 7.76 (td, *J* = 8.0, 1.6 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 4.0 Hz, 1H), 7.24 (ddd, *J* = 7.6, 4.8, 0.8 Hz, 1H), 6.90 (d, *J* = 4.0 Hz, 1H), 1.84 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 164.30, 160.12, 147.64, 139.89, 137.51, 134.57, 126.92, 126.79, 122.23, 119.63, 56.98, 27.66; HRMS (EI-TOF) calcd for C₁₃H₁₃ClN₂OS (M⁺): 280.0437, found: 280.0436.



5-bromo-N-(2-(pyridin-2-yl)propan-2-yl)thiophene-2-carboxamide **1v**

The title compound **1v** was prepared according to the general procedure (Method B). ¹H NMR (400 MHz, CDCl₃) δ 8.76 (br, 1H), 8.55 (d, *J* = 4.8 Hz, 1H), 7.76 (td, *J* = 8.0, 1.6 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.33 (d, *J* = 4.0 Hz, 1H), 7.24 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.04 (d, *J* = 4.0 Hz, 1H), 1.84 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) 164.28, 160.03, 147.64, 142.76, 137.51, 130.60, 127.67, 122.23, 119.63, 117.20, 56.99, 27.65; HRMS (EI-TOF) calcd for C₁₃H₁₃BrN₂OS (M⁺): 323.9932, found: 323.9939.




4-acetyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide **1ae**

The title compound **1ae** was prepared according to the general procedure (Method A). ¹H NMR (400 MHz, CDCl₃) δ 9.06 (br, 1H), 8.56 (d, *J* = 4.2 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.78 (td, *J* = 8.0, 1.7 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.23 (s, 1H), 2.65 (s, 3H), 1.89 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 197.76, 165.33, 164.53, 147.67, 140.16, 139.01, 137.55, 128.61, 127.45, 122.25, 119.72, 56.91, 27.53, 26.97.

2.2 Optimization of Reaction Conditions


Screening of Ni Salts



Entry ^a	Ni (10%)	Yield ^b of 3a
1	$\text{Ni}(\text{OTf})_2$	28%
2	$\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$	trace
3	NiBr_2	N.D.
4	NiCl_2	trace
5	$(\text{dppe})\text{NiCl}_2$	trace
6	$(\text{dppp})\text{NiCl}_2$	trace
7	$(\text{PPh}_3)_2\text{NiCl}_2$	trace
8	$\text{Ni}(\text{cod})_2$	trace
9	$(\text{DME})\text{NiCl}_2$	trace
10	NiCp_2	trace
11	$\text{Ni}(\text{acac})_2$	22%
12	$\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$	trace

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), $[\text{Ni}]$ (0.01 mmol), DME (0.02 mmol), Na_2CO_3 (0.2 mmol), DCE (1 mL), N_2 , 140°C. ^b Yield of ^1H NMR. N.D. = No Detection.


Screening of Ligands



Entry ^a	L (20%)	Yield ^b of 3a
1	BINAP	trace
2	PCy ₃	trace
3	DPPM	8%
4	DPPP	trace
5	DPPB	trace
6	BPy	N.D.
7	1,10-Phen	N.D.
8	BDMAE	15%
9	DME	60%(mono:di=3:1)
10	TMEDA	25%

^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), Ni(OTf)₂ (0.01 mmol), Ligands (0.02 mmol), Na₂CO₃ (0.2 mmol), DCE (1 mL), N₂, 140°C. ^b Yield of ¹H NMR. N.D. = No Detection.


Screening of Solvents



Entry ^a	Solvent	Yield ^b of 3a
1	DMF	11%
2	DMSO	15%
3	1,4-dioxane	18%
4	Toluenel	trace
5	<i>o</i> -xylene	trace
6	Isobutyronitrile	75%(mono:di=4:1)
7	DME	5%
8	DCM	trace
9	Acetonitrile	trace
10	Butyronitrile	16%
11	Pivalonitrile	81%(mono:di=3:1)


^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), Ni(OTf)₂ (0.01 mmol), DME (0.02 mmol), Na₂CO₃ (0.2 mmol), solvent (1.0 mL), N₂, 140°C, 12h. ^b Yield of ¹H NMR.

Screening of Bases



Entry ^a	Bases (2.0 eq.)	Yield ^b of 3a
1	Li_2CO_3	8%
2	Na_2CO_3	81%(mono:di=3:1)
3	K_2CO_3	N.D.
4	Cs_2CO_3	N.D.
5	NaHCO_3	99%(mono:di=1:2)
6	KHCO_3	90%(mono:di=1:3)
7	K_3PO_4	37%
8	K_2HPO_4	25%
9	KH_2PO_4	N.D.
10	NaOAc	N.D.





^a The reactions were carried out **1a** (0.1 mmol), **2a** (0.2 mmol), $\text{Ni}(\text{OTf})_2$ (0.01 mmol), DME (0.02 mmol), base (0.2 mmol), *t*-BuCN (1 mL), N_2 , 140 °C. ^b Yield of ^1H NMR. N.D. = No detection.




Entry ^a	Solvent	Yield ^b of 3a
1	0.5 mL	99%(mono:di=1:2.8)
2	2mL	83%(mono:di=2:1)
3	4 mL	79%(mono:di=1.5:1)
4	6mL	63%(mono:di=2:1)
5	8 mL	61%(mono:di=2:1)
6 ^c	0.5 mL	99%(mono:di=32:1)

^a The reactions were carried out **1a** (0.4 mmol), **2a** (0.8 mmol), $\text{Ni}(\text{OTf})_2$ (0.002 mmol), DME (0.004 mmol), NaHCO_3 (0.8 mmol), *t*-BuCN (x mL), N_2 , 150 °C, 24 h. ^b Yield of ^1H NMR. ^c **1a** (0.8 mmol), **2a** (0.4 mmol).


Screening of Directing Group




2.3 General Procedure for the Alkynylation



Condition A



Condition B



Condition C

Condition A:

To an oven-dried 50 mL screw-capped vial was added substrate **1a** (x mmol), **2a** (y mmol), Ni(OTf)₂ (0.8 mg, 0.002 mmol), NaHCO₃ (67.2 mg, 0.8 mmol), DME (0.004 mmol) in *t*-BuCN (0.5 mL). The mixture was stirred for 24 h at 150 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product.


Condition B:

To an oven-dried 50 mL screw-capped vial was added substrate **1a** (0.4 mmol), **2a** (1.6 mmol), Ni(OTf)₂ (0.8 mg, 0.002 mmol), NaHCO₃ (67.2 mg, 0.8 mmol), DME (0.004 mmol) in *t*-BuCN (0.5 mL). The mixture was stirred for 24 h at 150 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and

concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product.


Condition C:

To an oven-dried 50 mL screw-capped vial was added substrate **1a** (0.8 mmol), **2a** (0.4 mmol), Ni(OTf)₂ (0.8 mg, 0.002 mmol), NaHCO₃ (67.2 mg, 0.8 mmol), DME (0.004 mmol) in *t*-BuCN (0.5 mL). The mixture was stirred for 24 h at 130 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product.



N-(2-(Pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide **3a**


Following **Condition A**: **1a** (0.8 mmol), **2a** (0.4 mmol); ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 4.0 Hz, 1H), 8.40 (br, 1H), 7.80 (dd, *J* = 6.8, 3.6 Hz, 1H), 7.68 (td, *J* = 8.0, 2.0 Hz, 1H), 7.58 – 7.55 (m, 1H), 7.47 (d, *J* = 8.0 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.15 (dd, *J* = 6.4, 4.8 Hz, 1H), 1.87 (s, 6H), 1.07–1.02 (m, 21H); ¹³C NMR (100 MHz, CDCl₃) δ 166.19, 164.57, 148.04, 137.75, 136.81, 134.72, 129.78, 129.13, 128.68, 121.62, 120.13, 119.36, 105.36, 97.33, 57.68, 27.76, 18.65, 11.30; HRMS (EI-TOF) calcd for C₂₆H₃₆N₂OSi (M⁺): 420.2597, found: 420.2599.



N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide **4a**


Following **Condition B**: ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, *J* = 5.2 Hz, 1H), 8.41 (br, 1H), 7.70 (t, *J* = 7.2 Hz, 1H), 7.48 - 7.42 (m, 3H), 7.24 (t, *J* = 8.0 Hz, 1H), 7.15

(dd, $J = 6.4, 5.2$ Hz, 1H), 1.92 (s, 6H), 1.03 – 0.97 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.03, 164.58, 147.41, 142.42, 137.13, 133.82, 128.18, 121.80, 121.59, 119.49, 104.25, 95.04, 57.29, 27.58, 18.74, 11.38; HRMS (EI-TOF) calcd for $\text{C}_{37}\text{H}_{56}\text{N}_2\text{OSi}_2$ (M^+): 600.3931, found: 600.3932.




2-Methyl-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide
3b

Following **Condition A**: **1b** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.43 (d, $J = 4.8$ Hz, 1H), 8.16 (br, 1H), 7.71 (td, $J = 7.6, 1.6$ Hz, 1H), 7.46 (d, $J = 8.4$ Hz, 1H), 7.37 (d, $J = 6.4$ Hz, 1H), 7.21–7.15 (m, 3H), 2.37 (s, 3H), 1.92 (s, 6H), 1.02–0.97 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.60, 164.38, 147.47, 140.14, 137.00, 135.43, 131.23, 130.38, 128.14, 121.77, 120.48, 119.42, 105.06, 93.91, 57.13, 27.43, 19.33, 18.61, 11.27; HRMS (EI-TOF) calcd for $\text{C}_{27}\text{H}_{38}\text{N}_2\text{OSi}$ (M^+): 434.2753, found: 434.2755.




5-Methyl-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide
3c

Following **Condition A**: **1c** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.51 (dd, $J = 4.0, 0.8$ Hz, 1H), 8.36 (br, 1H), 7.69–7.64 (m, 2H), 7.46 (dd, $J = 8.0, 3.6$ Hz, 2H), 7.19–7.13 (m, 2H), 2.36 (s, 3H), 1.86 (s, 6H), 1.07–1.02 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.36, 164.82, 148.25, 139.21, 137.41, 136.84, 134.87, 130.78, 129.97, 121.67, 119.49, 117.24, 105.78, 96.68, 57.87, 27.95, 21.46, 18.79, 11.47; HRMS (EI-TOF) calcd for $\text{C}_{27}\text{H}_{38}\text{N}_2\text{OSi}$ (M^+): 434.2753, found: 434.2752.




N*-(2-(Pyridin-2-yl)propan-2-yl)-2-(trifluoromethyl)-6-((triisopropylsilyl)ethynyl)benzamide **3d*

Following **Condition A**: **1d** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.52 (br, 1H), 8.41 (d, $J = 4.8$ Hz, 1H), 7.75–7.71 (m, 2H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.45–7.41 (m, 2H), 7.17 (dd, $J = 6.8, 5.2$ Hz, 1H), 1.91 (s, 6H), 1.03–0.97 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.73, 164.25, 147.37, 138.76, 137.40, 137.29, 128.56, 127.98 (q, $J = 31.7$ Hz), 126.02 (q, $J = 4.8$ Hz), 123.65 (q, $J = 272.7$ Hz), 123.20, 121.98, 119.53, 103.41, 96.73, 57.49, 27.14, 18.71, 11.36; ^{19}F NMR (376 MHz, CDCl_3) δ 59.02; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{35}\text{F}_3\text{N}_2\text{OSi}$ (M^+): 488.2471, found: 488.2474.




N*-(2-(Pyridin-2-yl)propan-2-yl)-5-(trifluoromethyl)-2-((triisopropylsilyl)ethynyl)benzamide **3e*

Following **Condition A**: **1e** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.57 (br, 1H), 8.50 (d, $J = 4.4$ Hz, 1H), 8.06 (s, 1H), 7.71 (td, $J = 7.6, 1.6$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 7.2, 5.2$ Hz, 1H), 1.89 (s, 6H), 1.06–0.99 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.14, 164.34, 148.08, 138.89, 137.10, 135.21, 130.59 (q, $J = 33.0$ Hz), 126.41–126.23 (m), 123.92, 123.69 (q, $J = 270.8$ Hz), 121.92, 119.54, 103.94, 100.56, 57.87, 27.69, 18.71, 11.37; ^{19}F NMR (376 MHz, CDCl_3) δ 62.96; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{35}\text{F}_3\text{N}_2\text{OSi}$ (M^+): 488.2471, found: 488.2473.




2-Chloro-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide
3f

Following **Condition A**: **1f** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.44 (d, $J = 4.8$ Hz, 1H), 8.30 (br, 1H), 7.72 (td, $J = 7.6$, 1.6 Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.43 (dd, $J = 7.6$, 0.8 Hz, 1H), 7.35 (d, $J = 8.0$ Hz, 1H), 7.23 (t, $J = 8.0$ Hz, 1H), 7.17 (dd, $J = 7.2$, 5.2 Hz, 1H), 1.92 (s, 6H), 1.06–0.98 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.78, 164.32, 147.51, 139.64, 137.24, 132.22, 131.61, 129.77, 129.30, 122.96, 121.97, 119.56, 103.57, 95.94, 57.55, 27.51, 18.74, 11.38; **HRMS** (EI-TOF) calcd for $\text{C}_{26}\text{H}_{35}\text{ClN}_2\text{OSi}$ (M^+): 454.2207, found: 454.2209.



5-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide
3g


Following **Condition A**: **1g** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.50 (d, $J = 4.0$ Hz, 1H), 8.46 (br, 1H), 7.77 (d, $J = 2.0$ Hz, 1H), 7.69 (td, $J = 8.0$, 1.6 Hz, 1H), 7.47 (dd, $J = 14.8$, 8.0 Hz, 2H), 7.33 (dd, $J = 8.0$, 2.0 Hz, 1H), 7.17 (dd, $J = 6.4$, 4.8 Hz, 1H), 1.86 (s, 6H), 1.05 – 1.00 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.04, 164.42, 148.13, 139.56, 137.02, 135.97, 134.94, 130.00, 129.34, 121.85, 119.45, 118.76, 104.26, 98.51, 57.84, 27.74, 18.74, 11.39; **HRMS** (EI-TOF) calcd for $\text{C}_{26}\text{H}_{35}\text{ClN}_2\text{OSi}$ (M^+): 454.2207, found: 454.2203.



2-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide **3h**


Following **Condition A**: **1h** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.43 (d, $J = 4.4$ Hz, 1H), 8.35 (br, 1H), 7.72 (td, $J = 8.0$, 1.6 Hz, 1H), 7.47 – 7.42 (m, 2H), 7.34 (dd, $J = 8.0$, 0.8 Hz, 1H), 7.22 (t, $J = 8.0$ Hz, 1H), 7.17 (dd, $J = 6.4$, 4.8 Hz, 1H), 1.93 (s, 6H), 1.04 – 0.99 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 64.69,

164.15, 147.38, 139.55, 137.20, 132.11, 131.48, 129.68, 129.24, 122.83, 121.92, 119.47, 103.50, 95.80, 57.44, 27.41, 18.65, 11.28; **HRMS** (EI-TOF) calcd for $C_{26}H_{35}BrN_2OSi$ (M^+): 498.1702, found: 498.1705.




5-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide **3i**

Following **Condition A**: **1i** (0.4 mmol), **2a** (0.8 mmol); **1H NMR** (400 MHz, $CDCl_3$) δ 8.50 (br, 2H), 7.92 (d, $J = 1.6$ Hz, 1H), 7.69 (t, $J = 6.8$ Hz, 1H), 7.49–7.40 (m, 3H), 7.16 (dd, $J = 6.4, 5.2$ Hz, 1H), 1.87 (s, 6H), 1.05–1.00 (m, 21H); **^{13}C NMR** (100 MHz, $CDCl_3$) δ 164.84, 164.25, 147.98, 139.63, 136.95, 135.94, 132.78, 132.06, 122.92, 121.77, 119.34, 119.11, 104.20, 98.55, 57.71, 27.61, 18.65, 11.27; **HRMS** (EI-TOF) calcd for $C_{26}H_{35}BrN_2OSi$ (M^+): 498.1702, found: 498.1700.




2-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide **3g**

Following **Condition A**: **1g** (0.4 mmol), **2a** (0.8 mmol); **1H NMR** (400 MHz, $CDCl_3$) δ 8.45 (d, $J = 4.2$ Hz, 1H), 8.28 (br, 1H), 7.72 (td, $J = 8.0, 1.6$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.34–7.25 (m, 2H), 7.17 (dd, $J = 6.8, 5.2$ Hz, 1H), 7.07 (t, $J = 8.0$ Hz, 1H), 1.90 (s, 6H), 1.07–0.99 (m, 21H); **^{13}C NMR** (100 MHz, $CDCl_3$) δ 164.30, 162.77, 159.37 (d, $J = 246.9$ Hz), 147.60, 137.24, 130.01 (d, $J = 9.0$ Hz), 129.79 (d, $J = 3.2$ Hz), 128.73 (d, $J = 19.1$ Hz), 123.26 (d, $J = 5.0$ Hz), 121.96, 119.52, 116.22 (d, $J = 2.2$ Hz), 103.39, 96.10, 57.62, 27.64, 18.73, 11.38; **^{19}F NMR** (376 MHz, $CDCl_3$) δ 115.83; **HRMS** (EI-TOF) calcd for $C_{26}H_{35}FN_2OSi$ (M^+): 438.2503, found: 438.2500.




N-(2-(Pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 3k

¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 4.0 Hz, 1H), 8.35 (br, 1H), 7.64 (td, *J* = 7.6, 1.6 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 7.13 (dd, *J* = 6.8, 5.2 Hz, 1H), 6.87 (d, *J* = 8.8 Hz, 1H), 4.30 (m, 4H), 1.83 (s, 6H), 1.09-1.04 (m, 21H); ¹³C NMR (100 MHz, CDCl₃) δ 165.65, 164.98, 148.29, 145.97, 145.17, 136.73, 131.07, 122.37, 121.56, 119.46, 117.56, 110.06, 103.94, 100.18, 64.47, 64.20, 57.88, 28.07, 18.73, 11.46; HRMS (EI-TOF) calcd for C₂₈H₃₈N₂O₃Si (M⁺): 478.2652, found: 478.2655.




N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)-2-naphthamide 3l

Following **Condition A**: **1l** (0.4 mmol), **2a** (0.8 mmol); ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 2H), 8.32 (br, 1H), 8.09 (s, 1H), 7.85 (d, *J* = 7.2 Hz, 1H), 7.79 (d, *J* = 7.6 Hz, 1H), 7.68 (td, *J* = 8.0, 1.6 Hz, 1H), 7.54 - 7.48 (m, 3H), 7.15 (dd, *J* = 6.4, 5.2 Hz, 1H), 1.91 (s, 6H), 1.12 - 1.06 (m, 21H); ¹³C NMR (100 MHz, CDCl₃) δ 166.31, 164.74, 148.13, 136.90, 135.30, 134.48, 133.37, 132.45, 129.58, 128.73, 127.86, 127.50, 127.26, 121.71, 119.47, 117.44, 105.84, 96.49, 57.84, 27.89, 18.81, 11.47; HRMS (EI-TOF) calcd for C₃₀H₃₈N₂OSi (M⁺): 470.2753, found: 470.2759.




N-(2-(Pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)-1-naphthamide 3m

Following **Condition A**: **1m** (0.4 mmol), **2a** (0.8 mmol); **¹H NMR** (400 MHz, CDCl₃) δ 8.43 (br, 1H), 8.39 (d, *J* = 4.0 Hz, 1H), 8.04 (d, *J* = 6.8 Hz, 1H), 7.79 (m, 1H), 7.76 (d, *J* = 8.8 Hz, 1H), 7.71 (td, *J* = 8.0, 1.6 Hz, 1H), 7.50 (m, 4H), 7.14 (dd, *J* = 6.8, 5.2 Hz, 1H), 2.02 (s, 6H), 1.05-1.00 (m, 21H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.26, 164.31, 147.56, 138.64, 137.16, 133.03, 130.25, 129.79, 128.64, 127.99, 127.35, 126.91, 125.90, 121.92, 119.52, 117.88, 105.44, 95.77, 57.56, 27.64, 18.75, 11.39; **HRMS** (EI-TOF) calcd for C₃₀H₃₈N₂OSi (M⁺): 470.2753, found: 470.2757.



2-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-4-((triisopropylsilyl)ethynyl)nicotinamide 3n

Following **Condition A**: **1n** (0.4 mmol), **2a** (0.8 mmol); **¹H NMR** (400 MHz, CDCl₃) δ 8.53 (br, 1H), 8.44 (d, *J* = 4.0 Hz, 1H), 8.33 (d, *J* = 5.2 Hz, 1H), 7.75 (t, *J* = 7.2 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.33 (d, *J* = 4.8 Hz, 1H), 7.20 (dd, *J* = 6.4, 5.2 Hz, 1H), 1.92 (s, 6H), 1.10 – 1.00 (m, 21H); **¹³C NMR** (100 MHz, CDCl₃) δ 163.87, 163.21, 148.95, 148.65, 147.41, 137.41, 134.73, 131.86, 126.20, 122.13, 119.50, 102.40, 101.00, 57.57, 27.33, 18.64, 11.23; **HRMS** (EI-TOF) calcd for C₂₅H₃₄ClN₃OSi (M⁺): 455.2160, found: 455.2158.




5-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)nicotinamide 3o

Following **Condition A**: **1o** (0.4 mmol), **2a** (0.8 mmol); **¹H NMR** (400 MHz, CDCl₃) δ 8.55-8.48 (m, 3H), 7.86 (s, 1H), 7.71 (td, *J* = 8.0, 5.2 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.18 (dd, *J* = 6.8, 4.8 Hz, 1H), 2.36 (s, 3H), 1.88 (s, 6H), 1.07-1.01 (m, 21H); **¹³C NMR** (100 MHz, CDCl₃) δ 165.32, 164.34, 151.75, 148.05, 137.14, 137.07, 136.54,


134.23, 133.23, 121.88, 119.41, 104.53, 96.25, 57.80, 27.67, 18.75, 18.39, 11.44;

HRMS (EI-TOF) calcd for $C_{26}H_{37}N_3OSi$ (M^+): 435.2706, found: 435.2711.




3-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 3p

Following **Condition A**: **1p** (0.4 mmol), **2a** (0.8 mmol); 1H NMR (400 MHz, $CDCl_3$) δ 8.62 (s, 2H), 8.52 (br, 1H), 8.44 (d, $J = 4.0$ Hz, 1H), 7.75 (td, $J = 8.0, 1.6$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.22 – 7.19 (m, 1H), 1.92 (s, 6H), 1.05 – 1.00 (m, 21H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.55, 162.33, 152.03, 148.54, 147.32, 145.16, 137.36, 128.38, 122.09, 119.38, 118.66, 99.93, 99.80, 57.62, 27.35, 18.57, 11.15; **HRMS** (EI-TOF) calcd for $C_{25}H_{34}ClN_3OSi$ (M^+): 455.2160, found: 455.2159.




2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 3q

Following **Condition A**: **1q** (0.4 mmol), **2a** (0.8 mmol); 1H NMR (400 MHz, $CDCl_3$) δ 8.69 (s, 1H), 8.61 (br, 1H), 8.50 (d, $J = 4.0$ Hz, 1H), 7.71 (td, $J = 8.0, 1.6$ Hz, 1H), 7.50 (s, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 6.4, 4.8$ Hz, 1H), 2.58 (s, 3H), 1.88 (s, 6H), 1.07 – 1.01 (m, 21H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 164.43, 163.94, 158.52, 154.48, 147.88, 144.48, 136.95, 121.78, 121.64, 119.23, 113.47, 102.09, 99.41, 57.68, 27.46, 24.30, 18.54, 11.16; **HRMS** (EI-TOF) calcd for $C_{26}H_{38}N_3OSi$ ($M+H$) $^+$: 436.2784, found: 436.2794.




2-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 3r

Following **Condition A**: **1r** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.67 (br, 1H), 8.55 (s, 1H), 8.49 (dd, $J = 4.0, 0.8$ Hz, 1H), 7.73 (td, $J = 8.0, 1.6$ Hz, 1H), 7.64 (s, 1H), 7.43 (d, $J = 8.4$ Hz, 1H), 7.20 (ddd, $J = 7.6, 5.2, 0.8$ Hz, 1H), 1.86 (s, 6H), 1.05–0.99 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 163.85, 163.22, 155.03, 151.30, 148.00, 147.40, 137.31, 123.14, 122.13, 119.43, 115.79, 101.86, 100.67, 57.95, 27.54, 18.70, 11.33; **HRMS** (EI-TOF) calcd for $\text{C}_{25}\text{H}_{34}\text{ClN}_3\text{OSi}$ (M^+): 455.2160, found: 455.2161.



2-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 3s


Following **Condition A**: **1s** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.72 (br, 1H), 8.52 (s, 1H), 8.49 (d, $J = 4.0$ Hz, 1H), 7.79 (s, 1H), 7.73 (t, $J = 7.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.21 (dd, $J = 6.4, 5.2$ Hz, 1H), 1.87 (s, 6H), 1.05–1.00 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 163.62, 162.93, 155.01, 147.80, 146.89, 141.59, 137.21, 126.59, 122.02, 119.29, 116.00, 101.86, 100.53, 57.78, 27.37, 18.56, 11.15; **HRMS** (EI-TOF) calcd for $\text{C}_{25}\text{H}_{34}\text{BrN}_3\text{OSi}$ (M^+): 499.1655, found: 499.1657.



N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)thiophene-2-carboxamide 3t


Following **Condition A**: **1t** (0.4 mmol), **2a** (0.8 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.55 (d, $J = 4.0$ Hz, 1H), 8.14 (br, 1H), 7.64 (td, $J = 7.6, 1.6$ Hz, 1H), 7.45 (d, $J =$

8.0 Hz, 1H), 7.34 (d, $J = 5.2$ Hz, 1H), 7.14-7.11 (m, 2H), 1.83 (s, 6H), 1.12–1.06 (m, 21); ^{13}C NMR (100 MHz, CDCl_3) δ 164.51, 160.33, 148.61, 142.83, 136.61, 132.69, 128.64, 121.58, 120.09, 119.25, 101.04, 99.08, 58.19, 28.28, 18.71, 11.28; **HRMS** (EI-TOF) calcd for $\text{C}_{24}\text{H}_{34}\text{N}_2\text{OSSi}$ (M^+): 426.2161, found: 426.2165.




5-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)thiophene-2-carboxamide 3u

Following **Condition A**: **1u** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, $J = 4.0$ Hz, 1H), 8.06 (br, 1H), 7.65 (td, $J = 8.0, 1.6$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.14 (dd, $J = 7.2, 5.6$ Hz, 1H), 6.94 (s, 1H), 1.81 (s, 6H), 1.10 – 1.05 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.35, 159.61, 148.74, 141.58, 136.75, 134.14, 131.29, 121.76, 119.62, 119.28, 100.13, 99.96, 58.33, 28.29, 18.75, 11.32; **HRMS** (EI-TOF) calcd for $\text{C}_{24}\text{H}_{33}\text{ClN}_2\text{OSSi}$ (M^+): 460.1771, found: 460.1777.




5-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)thiophene-2-carboxamide 3v

Following **Condition A**: **1v** (0.4 mmol), **2a** (0.8 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, $J = 4.0$ Hz, 1H), 8.05 (br, 1H), 7.65 (td, $J = 8.0, 1.6$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.14 (td, $J = 5.6, 1.6$ Hz, 1H), 7.07 (s, 1H), 1.80 (s, 6H), 1.10 – 1.05 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.35, 159.54, 148.75, 144.35, 136.75, 134.90, 121.76, 120.48, 119.29, 116.98, 100.28, 99.69, 58.33, 28.29, 18.76, 11.33; **HRMS** (EI-TOF) calcd for $\text{C}_{24}\text{H}_{33}\text{BrN}_2\text{OSSi}$ (M^+): 504.1266, found: 504.1269.




4-Methyl-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3w

Following **Condition A**: **1w** (0.8 mmol), **2a** (0.4 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.50 (d, $J = 4.4$ Hz, 1H), 8.35 (br, 1H), 7.73 (d, $J = 8.0$ Hz, 1H), 7.66 (td, $J = 7.6$, 1.6 Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.36 (s, 1H), 7.18 (d, $J = 8.0$ Hz, 1H), 7.13 (dd, $J = 6.8$, 5.2 Hz, 1H), 2.35 (s, 3H), 1.85 (s, 6H), 1.08–1.03 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.16, 164.87, 148.22, 140.18, 136.79, 135.18, 134.91, 129.77, 129.54, 121.62, 120.00, 119.45, 105.84, 97.12, 57.82, 27.98, 21.12, 18.79, 11.45; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{38}\text{N}_2\text{OSi}$ (M^+): 434.2753, found: 434.2752.




4-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4w

Following **Condition B**: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.41 (d, $J = 4.0$ Hz, 1H), 8.37 (br, 1H), 7.70 (t, $J = 7.6$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.28 (s, 2H), 7.14 (dd, $J = 6.4$, 5.2 Hz, 1H), 2.31 (s, 3H), 1.91 (s, 6H), 1.03 – 0.98 (m, 42H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.15, 164.60, 147.37, 139.92, 138.10, 137.08, 134.38, 121.75, 121.42, 119.47, 104.47, 94.41, 57.22, 27.55, 20.84, 18.72, 11.37; **HRMS** (EI-TOF) calcd for $\text{C}_{38}\text{H}_{58}\text{N}_2\text{OSi}_2$ (M^+): 614.4088, found: 614.4093.




4-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3x

Following **Condition A**: **1x** (0.8 mmol), **2a** (0.4 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, $J = 4.0$ Hz, 1H), 8.37 (br, 1H), 7.85 (d, $J = 8.8$ Hz, 1H), 7.67 (td, $J = 8.0$, 1.6 Hz, 1H), 7.46 (d, $J = 8.4$ Hz, 1H), 7.15 (dd, $J = 7.2$, 5.2 Hz, 1H), 7.04 (d, $J = 2.4$ Hz, 1H), 6.91 (dd, $J = 8.8$, 2.4 Hz, 1H), 3.83 (s, 3H), 1.86 (s, 6H), 1.09–1.04 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.82, 164.72, 160.61, 148.32, 136.92, 131.63, 129.67, 121.68, 121.44, 119.74, 119.46, 114.63, 105.55, 97.88, 57.81, 55.50, 28.00, 18.72, 11.36; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{38}\text{N}_2\text{O}_2\text{Si}$ (M^+): 450.2703, found: 450.2704.



4-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4x


Following **Condition B**: ^1H NMR (400 MHz, CDCl_3) δ 8.42 (d, $J = 4.0$ Hz, 1H), 8.38 (br, 1H), 7.70 (t, $J = 6.4$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.14 (dd, $J = 7.0$, 5.2 Hz, 1H), 7.00 (s, 2H), 3.81 (s, 3H), 1.92 (s, 6H), 1.04 – 0.98 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.86, 164.54, 158.60, 147.31, 137.06, 135.82, 122.75, 121.71, 119.42, 119.25, 104.22, 94.72, 57.12, 55.55, 27.47, 18.65, 11.30; **HRMS** (EI-TOF) calcd for $\text{C}_{38}\text{H}_{58}\text{N}_2\text{O}_2\text{Si}_2$ (M^+): 630.4037, found: 630.4036.



4-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3y


Following **Condition A**: **1y** (0.8 mmol), **2a** (0.4 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.51 (d, $J = 4.0$ Hz, 1H), 8.38 (br, 1H), 7.80 (dd, $J = 6.8$, 4.0 Hz, 1H), 7.68 (td, $J =$

8.0, 1.6 Hz, 1H), 7.58–7.55 (m, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.38–7.36 (m, 2H), 7.17–7.14 (m, 1H), 1.87 (s, 6H), 1.07–1.02 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.42, 164.65, 163.03 (d, $J = 249.3$ Hz), 148.19, 136.97, 134.36, 131.75 (d, $J = 9.1$ Hz), 122.38 (d, $J = 9.7$ Hz), 121.80, 121.07 (d, $J = 22.9$ Hz), 119.47, 116.30 (d, $J = 21.3$ Hz), 104.17, 98.99, 57.83, 27.84, 18.75, 11.41; ^{19}F NMR (376 MHz, CDCl_3) δ 110.89; HRMS (EI-TOF) calcd for $\text{C}_{26}\text{H}_{35}\text{FN}_2\text{OSi}$ (M^+): 438.2503, found: 438.24503.



4-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4y


Following **Condition B**: ^1H NMR (400 MHz, CDCl_3) δ 8.51 (br, 1H), 8.42 (d, $J = 4.4$ Hz, 1H), 7.71 (td, $J = 8.0, 1.6$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.17 (d, $J = 8.8$ Hz, 3H), 1.93 (s, 6H), 1.03 – 0.98 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.21, 164.30, 161.21 (d, $J = 247.2$ Hz), 147.29, 139.06 (d, $J = 3.2$ Hz), 137.18, 123.56 (d, $J = 10.2$ Hz), 121.84, 120.52 (d, $J = 22.5$ Hz), 119.41, 103.05 (d, $J = 2.7$ Hz), 96.47, 57.19, 27.44, 18.62, 11.27; ^{19}F NMR (376 MHz, CDCl_3) δ 113.07; HRMS (EI-TOF) calcd for $\text{C}_{37}\text{H}_{57}\text{FN}_2\text{OSi}_2$ (M^+): 618.3837, found: 618.3842.



4-Chloro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3z


Following **Condition A**: **1z** (0.8 mmol), **2a** (0.4 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, $J = 4.4$ Hz, 1H), 8.42 (br, 1H), 7.74–7.67 (m, 2H), 7.51 (d, $J = 2.0$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.34 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.16 (dd, $J = 6.8, 5.2$ Hz, 1H), 1.86 (s, 6H), 1.06–1.01 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.45, 164.53, 148.11, 137.04, 136.57, 135.76, 134.13, 130.73, 129.05, 121.94, 121.84, 119.48,

103.95, 99.02, 57.81, 27.78, 18.75, 11.41; **HRMS** (EI-TOF) calcd for $C_{26}H_{35}ClN_2OSi$ (M^+): 454.2207, found: 454.2212.




4-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4z

Following **Condition B**: 1H NMR (400 MHz, $CDCl_3$) δ 8.53 (br, 1H), 8.41 (d, $J = 4.4$ Hz, 1H), 7.71 (t, $J = 6.8$ Hz, 1H), 7.44 - 7.41 (m, 3H), 7.16 (dd, $J = 7.2, 5.2$ Hz, 1H), 1.92 (s, 6H), 1.03 – 0.98 (m, 42H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.07, 164.20, 147.26, 140.82, 137.20, 133.68, 133.21, 123.14, 121.85, 119.37, 102.81, 96.67, 57.19, 27.43, 18.63, 11.25; **HRMS** (EI-TOF) calcd for $C_{37}H_{55}ClN_2OSi_2$ (M^+): 634.3541, found: 634.3546.




4-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3aa

Following **Condition A**: **1aa** (0.8 mmol), **2a** (0.4 mmol); 1H NMR (400 MHz, $CDCl_3$) δ 8.49 (d, $J = 4.8$ Hz, 1H), 8.44 (br, 1H), 7.71-7.63 (m, 3H), 7.49 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.16 (dd, $J = 7.2, 4.8$ Hz, 1H), 1.86 (s, 6H), 1.06–1.01 (m, 21H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.50, 164.45, 148.06, 137.09, 136.99, 136.91, 131.91, 130.70, 123.77, 122.12, 121.80, 119.41, 103.75, 98.99, 57.75, 27.72, 18.72, 11.36; **HRMS** (EI-TOF) calcd for $C_{26}H_{35}BrN_2OSi$ (M^+): 498.1702, found: 498.1705.




4-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4aa

Following **Condition B**: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.48 (br, 1H), 8.42 (d, $J = 4.4$ Hz, 1H), 7.71 (td, $J = 7.6, 1.6$ Hz, 1H), 7.59 (s, 2H), 7.41 (d, $J = 8.0$ Hz, 1H), 7.16 (dd, $J = 6.8, 5.2$ Hz, 1H), 1.90 (s, 6H), 1.02–0.97 (m, 42H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.19, 164.36, 147.39, 141.28, 137.23, 136.12, 123.36, 121.89, 121.49, 119.45, 102.76, 96.88, 57.30, 27.53, 18.71, 11.35; **HRMS** (EI-TOF) calcd for $\text{C}_{37}\text{H}_{55}\text{BrN}_2\text{OSi}_2$ (M^+): 678.3036, found: 678.3034.




2-Methyl-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide 3ab

Following **Condition A**: **1ab** (0.8 mmol), **2a** (0.4 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.54 (br, 1H), 8.48 (d, $J = 4.4$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.77 (s, 1H), 7.71 (td, $J = 7.86, 1.6$ Hz, 1H), 7.60 (d, $J = 8.4$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 6.8, 4.8$ Hz, 1H), 1.88 (s, 6H), 1.06–1.01 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.41, 164.22, 147.88, 141.69, 137.07, 131.82 (q, $J = 32.8$ Hz), 131.26 (q, $J = 2.8$ Hz), 129.49, 127.48, 125.10 (q, $J = 3.6$ Hz), 123.41 (q, $J = 270.9$ Hz), 121.86, 121.20, 119.38, 103.48, 98.94, 57.68, 27.56, 18.63, 11.30; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ 60.04; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{35}\text{F}_3\text{N}_2\text{OSi}$ (M^+): 488.2471, found: 488.2474.




N-(2-(pyridin-2-yl)propan-2-yl)-4-(trifluoromethyl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4ab

Following **Condition B**: ^1H NMR (400 MHz, CDCl_3) δ 8.53 (br, 1H), 8.32 (d, $J = 4.0$ Hz, 1H), 7.64 (td, $J = 8.0, 1.2$ Hz, 1H), 7.59 (s, 2H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.08 (dd, $J = 6.4, 4.8$ Hz, 1H), 1.85 (s, 6H), 0.95 – 0.90 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.89, 164.10, 147.30, 145.06, 137.31, 130.87 (q, $J = 33.4$ Hz), 130.02 (q, $J = 3.0$ Hz), 123.17 (q, $J = 271.2$ Hz), 122.63, 121.96, 119.40, 102.64, 97.33, 57.32, 27.50, 18.66, 11.30; ^{19}F NMR (376 MHz, CDCl_3) δ 63.12; **HRMS** (EI-TOF) calcd for $\text{C}_{38}\text{H}_{55}\text{F}_3\text{N}_2\text{OSi}_2$ (M^+): 688.3805, found: 688.3804.




4-Nitro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3ac

Following **Condition A**: **1ac** (0.8 mmol), **2a** (0.4 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.66 (br, 1H), 8.48 (d, $J = 4.4$ Hz, 1H), 8.36 (d, $J = 2.4$ Hz, 1H), 8.18 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.86 (d, $J = 8.4$ Hz, 1H), 7.74 (td, $J = 8.0, 2.0$ Hz, 1H), 7.46 (d, $J = 8.10$ Hz, 1H), 7.20 (dd, $J = 7.2, 5.6$ Hz, 1H), 1.89 (s, 6H), 1.06–1.01 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.94, 164.02, 148.20, 147.85, 144.22, 137.34, 130.08, 129.28, 123.15, 122.18, 122.09, 119.48, 102.55, 100.19, 57.79, 27.54, 18.69, 11.34; **HRMS** (EI-TOF) calcd for $\text{C}_{26}\text{H}_{35}\text{N}_3\text{O}_3\text{Si}$ (M^+): 465.2448, found: 465.2446.




4-nitro-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4ac

Following **Condition B**: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.73 (br, 1H), 8.42 (d, $J = 4.4$ Hz, 1H), 8.26 (s, 2H), 7.76 (t, $J = 8.0$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.20 (dd, $J = 6.4, 5.2$ Hz, 1H), 1.95 (s, 6H), 1.05 – 1.00 (m, 42H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.16, 163.76, 147.18, 147.06, 147.00, 137.37, 127.79, 123.32, 122.00, 119.33, 101.78, 98.62, 57.32, 27.40, 18.56, 11.19; **HRMS** (EI-TOF) calcd for $\text{C}_{37}\text{H}_{55}\text{N}_3\text{O}_3\text{Si}_2$ (M^+): 645.3782, found: 645.3775.




4-Cyano-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3ad

Following **Condition A**: **1ad** (0.8 mmol), **2a** (0.4 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.59 (br, 1H), 8.48 (d, $J = 4.4$ Hz, 1H), 7.82 (dd, $J = 4.5, 3.1$ Hz, 2H), 7.83–7.81 (m, 2H), 7.73 (td, 8.0, 1.6 Hz, 1H), 7.63 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.45 (d, $J = 8.4$ Hz, 1H), 7.20 (dd, $J = 7.6, 5.2$ Hz, 1H), 1.88 (s, 6H), 1.05–1.00 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.03, 164.11, 147.90, 142.37, 138.10, 137.31, 131.56, 129.82, 122.06, 121.89, 119.51, 117.66, 113.90, 102.67, 100.26, 57.81, 27.59, 18.71, 11.35; **HRMS** (EI-TOF) calcd for $\text{C}_{27}\text{H}_{35}\text{N}_3\text{OSi}$ (M^+): 445.2549, found: 445.2551.




4-Cyano-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4ad

Following **Condition B**: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.62 (br, 1H), 8.42 (d, $J = 4.8$ Hz, 1H), 7.74 (td, $J = 7.6, 1.2$ Hz, 1H), 7.71 (s, 2H), 7.42 (d, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 7.6, 5.2$ Hz, 1H), 1.91 (s, 6H), 1.06–0.97 (m, 42H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.40, 164.06, 147.35, 145.50, 137.38, 136.42, 123.25, 122.04, 119.44, 117.17, 112.99, 101.88, 98.61, 57.44, 27.52, 18.68, 11.32; **HRMS** (EI-TOF) calcd for $\text{C}_{38}\text{H}_{55}\text{N}_3\text{OSi}_2$ (M^+): 625.3884, found: 625.3882.



4-acetyl-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3ae


Following **Condition A**: **1ae** (0.8 mmol), **2a** (0.4 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.54 (br, 1H), 8.49 (d, $J = 4.0$ Hz, 1H), 8.10 (s, 1H), 7.92 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.83 (d, $J = 8.4$ Hz, 1H), 7.71 (td, $J = 8.0, 1.2$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 6.4, 4.8$ Hz, 1H), 2.63 (s, 3H), 1.89 (s, 6H), 1.13 – 1.01 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 196.93, 165.71, 164.29, 147.95, 142.19, 137.77, 137.07, 134.44, 129.35, 128.13, 121.87, 120.94, 119.41, 104.10, 98.23, 57.72, 27.63, 26.82, 18.70, 11.35; **HRMS** (EI-TOF) calcd for $\text{C}_{28}\text{H}_{38}\text{N}_2\text{O}_2\text{Si}$ (M^+): 462.2703, found: 462.2712.



4-acetyl-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide

4ae


Following Condition B: ^1H NMR (400 MHz, CDCl_3) δ 8.58 (br, 1H), 8.41 (d, J = 4.4 Hz, 1H), 8.00 (s, 2H), 7.73 (t, J = 6.8 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.17 (dd, J = 6.4, 5.2 Hz, 1H), 2.62 (s, 3H), 1.94 (s, 6H), 1.05 – 0.99 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 196.39, 165.20, 164.13, 147.27, 145.69, 137.25, 136.71, 133.16, 122.26, 121.90, 119.38, 103.14, 96.42, 57.27, 27.49, 26.78, 18.66, 11.29; HRMS (EI-TOF) calcd for $\text{C}_{39}\text{H}_{58}\text{N}_2\text{O}_2\text{Si}_2$ (M^+): 642.4037, found: 642.4036.



Methyl

4-((2-(pyridin-2-yl)propan-2-yl)carbamoyl)-3-((triisopropylsilyl)ethynyl)benzoate 3af


Following **Condition A**: **1af** (0.8 mmol), **2a** (0.4 mmol); ^1H NMR (400 MHz, CDCl_3) δ 8.52 (br, 1H), 8.49 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.00 (dd, J = 8.0, 1.6 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.71 (td, J = 8.0, 1.6 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.19 – 7.16 (m, 1H), 3.94 (s, 3H), 1.89 (s, 6H), 1.07 – 1.01 (m, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.91, 165.76, 164.30, 147.95, 142.18, 137.05, 135.73, 131.29, 129.39, 129.11, 121.84, 120.71, 119.41, 104.05, 98.07, 57.71, 52.50, 27.62, 18.69, 11.34; HRMS (EI-TOF) calcd for $\text{C}_{28}\text{H}_{38}\text{N}_2\text{O}_3\text{Si}_2$ (M^+): 478.2652, found: 478.2659.



methyl


4-((2-(pyridin-2-yl)propan-2-yl)carbamoyl)-3,5-bis((triisopropylsilyl)ethynyl)benzoate 4af

Following **Condition B**: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.58 (br, 1H), 8.41 (d, $J = 4.0$ Hz, 1H), 8.10 (s, 2H), 7.73 (t, $J = 6.4$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.17 (dd, $J = 6.4, 4.8$ Hz, 1H), 3.95 (s, 3H), 1.94 (s, 6H), 1.04 – 0.99 (m, 42H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.46, 165.23, 164.12, 147.25, 145.64, 137.22, 134.40, 130.19, 122.05, 121.87, 119.36, 103.09, 96.24, 57.25, 52.55, 27.46, 18.63, 11.26; **HRMS** (EI-TOF) calcd for $\text{C}_{39}\text{H}_{58}\text{N}_2\text{O}_3\text{Si}_2$ (M^+): 658.3986, found: 658.3988.




3-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 3ag

Following **Condition A**: **1ag** (0.8 mmol), **2a** (0.4 mmol); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.50 (d, $J = 4.8$ Hz, 1H), 8.45 (br, 1H), 7.69 (td, $J = 8.0, 1.6$ Hz, 1H), 7.56 (d, $J = 7.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.33 (td, $J = 8.0, 5.6$ Hz, 1H), 7.18-7.13 (m, 2H), 1.87 (s, 6H), 1.07–1.02 (m, 21H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.34 (d, $J = 2.9$ Hz), 164.52, 164.23 (d, $J = 251.1$ Hz), 162.98, 148.10, 140.31, 137.02, 129.69 (d, $J = 8.5$ Hz), 124.56 (d, $J = 3.3$ Hz), 121.83, 119.47, 116.91 (d, $J = 11.8$ Hz), 109.55 (d, $J = 17.2$ Hz, 2H), 104.09 (d, $J = 4.8$ Hz), 97.49, 57.81, 27.76, 18.67, 11.37; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ 107.44; **HRMS** (EI-TOF) calcd for $\text{C}_{26}\text{H}_{35}\text{FN}_2\text{OSi}$ (M^+): 438.2503, found: 438.2499.




3-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-2,6-bis((triisopropylsilyl)ethynyl)benzamide 4ag

Following **Condition B**: ^1H NMR (400 MHz, CDCl_3) δ 8.49 (br, 1H), 8.43 (d, $J = 4.0$ Hz, 1H), 7.71 (td, $J = 8.0, 1.6$ Hz, 1H), 7.46–7.42 (m, 2H), 7.16 (dd, $J = 6.4, 4.8$ Hz, 1H), 7.02 (t, $J = 8.4$ Hz, 1H), 1.92 (s, 6H), 1.03–0.97 (m, 42H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.84 (d, $J = 2.4$ Hz), 164.40, 163.42 (d, $J = 254.6$ Hz), 147.42, 144.40, 137.22, 135.20 (d, $J = 8.3$ Hz), 121.90, 119.48, 117.52 (d, $J = 4.1$ Hz), 115.72 (d, $J = 22.3$ Hz), 110.88, 103.32, 101.87 (d, $J = 4.4$ Hz), 96.62, 94.61, 57.37, 27.56, 18.73, 18.70, 11.40, 11.34; ^{19}F NMR (376 MHz, CDCl_3) δ 105.83; **HRMS** (EI-TOF) calcd for $\text{C}_{37}\text{H}_{55}\text{FN}_2\text{OSi}_2$ (M^+): 618.3837, found: 618.3839.




2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-6-((trimethylsilyl)ethynyl)benzamide 5a

Following **Condition C**: ^1H NMR (400 MHz, CDCl_3) δ 8.46 (d, $J = 4.0$ Hz, 1H), 8.11 (br, 1H), 7.72 (td, $J = 8.0, 1.6$ Hz, 1H), 7.49 (d, $J = 8.0$ Hz, 1H), 7.34 (d, $J = 6.8$ Hz, 1H), 7.21 – 7.17 (m, 3H), 2.38 (s, 3H), 1.92 (s, 6H), 0.10 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.63, 164.46, 147.64, 140.44, 137.15, 135.64, 130.74, 130.63, 128.34, 121.95, 120.22, 119.61, 103.04, 97.41, 57.30, 27.60, 19.50, -0.08; **HRMS** (EI-TOF) calcd for $\text{C}_{21}\text{H}_{26}\text{N}_2\text{OSi}$ (M^+): 350.1814, found: 350.1822.




2-(hex-1-yn-1-yl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide 5b

Following **Condition C**: ^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, $J = 4.8$ Hz, 1H), 7.98 (br, 1H), 7.72 (t, $J = 8.0$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 1H), 7.27 – 7.25 (m, 1H), 7.19 – 7.16 (m, 2H), 7.11 (d, $J = 7.2$ Hz, 1H), 2.37 (s, 3H), 2.31 (t, $J = 7.2$ Hz, 2H), 1.91 (s, 6H), 1.50 – 1.43 (m, 2H), 1.39 – 1.33 (m, 2H), 0.82 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.23, 164.56, 147.69, 140.49, 137.15, 135.35, 129.92, 129.68, 128.32, 121.93, 121.18, 119.63, 93.59, 78.70, 57.30, 30.76, 27.65, 22.13, 19.44, 19.40, 13.70; **HRMS** (EI-TOF) calcd for $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}$ (M^+): 334.2045, found: 334.2047.


**2-methyl-6-(phenylethynyl)-N-(2-(pyridin-2-yl)propan-2-yl)benzamide 5c**

Following **Condition C**: ^1H NMR (400 MHz, CDCl_3) δ 8.44 (d, $J = 4.4$ Hz, 1H), 8.09 (br, 1H), 7.64 (td, $J = 8.0, 1.6$ Hz, 1H), 7.47 (d, $J = 8.4$ Hz, 1H), 7.42 – 7.36 (m, 3H), 7.26 – 7.23 (m, 4H), 7.19 (d, $J = 7.2$ Hz, 1H), 7.16 – 7.13 (m, 1H), 2.42 (s, 3H), 1.91 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.92, 164.44, 147.70, 140.53, 137.16, 135.57, 131.67, 130.54, 129.97, 128.49, 128.32, 123.34, 121.95, 120.42, 119.63, 92.22, 87.69, 57.44, 27.70, 19.45; **HRMS** (EI-TOF) calcd for $\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}$ (M^+): 354.1732, found: 354.1732.

**2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-6-(p-tolyethynyl)benzamide 5d**


Following **Condition C**: ^1H NMR (400 MHz, CDCl_3) δ 8.43 (d, $J = 4.8$ Hz, 1H), 8.08 (br, 1H), 7.64 (td, $J = 8.0, 1.6$ Hz, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 1H), 7.27 (d, $J = 8.4$ Hz, 2H), 7.22 (d, $J = 7.6$ Hz, 1H), 7.18 – 7.12 (m, 2H), 7.05 (d, $J = 7.6$ Hz, 2H), 2.41 (s, 3H), 2.31 (s, 3H), 1.90 (s, 6H); ^{13}C NMR (100 MHz,

CDCl₃) δ 167.96, 164.41, 147.67, 140.40, 138.44, 137.12, 135.50, 131.53, 130.33, 129.90, 129.07, 128.44, 121.91, 120.57, 120.23, 119.61, 92.43, 87.00, 57.41, 27.68, 21.56, 19.42; **HRMS** (EI-TOF) calcd for C₂₅H₂₄N₂O (M⁺): 368.1889, found: 368.1896.



2-((4-methoxyphenyl)ethynyl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide 5e


Following **Condition C**: ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, *J* = 4.4 Hz, 1H), 8.06 (br, 1H), 7.64 (td, *J* = 8.0, 1.6 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.23 (t, *J* = 7.6 Hz, 1H), 7.17 – 7.13 (m, 2H), 6.77 (d, *J* = 8.8 Hz, 2H), 3.77 (s, 3H), 2.41 (s, 3H), 1.90 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 168.01, 164.42, 159.65, 147.68, 140.33, 137.12, 135.46, 133.09, 130.19, 129.80, 128.44, 121.92, 120.70, 119.61, 115.44, 113.95, 92.27, 86.35, 57.41, 55.35, 27.69, 19.42; **HRMS** (EI-TOF) calcd for C₂₅H₂₄N₂O₂ (M⁺): 384.1838, found: 384.1836.



2-((4-(tert-butyl)phenyl)ethynyl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide 5f


Following **Condition C**: ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, *J* = 4.8 Hz, 1H), 8.08 (br, 1H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.39 (d, *J* = 7.6 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.26 (d, *J* = 8.8 Hz, 2H), 7.22 (d, *J* = 7.6 Hz, 1H), 7.18 – 7.11 (m, 2H), 2.41 (s, 3H), 1.91 (s, 6H), 1.28 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 167.97, 164.40, 151.56, 147.67, 140.34, 137.11, 135.47, 131.37, 130.30, 129.97,

128.43, 125.29, 121.90, 120.59, 120.26, 119.61, 92.41, 87.02, 57.41, 34.83, 31.24, 27.70, 19.41; **HRMS** (EI-TOF) calcd for $C_{28}H_{30}N_2O$ (M^+): 410.2358, found: 410.2359.



2-((4-chlorophenyl)ethynyl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide
5g


Following **Condition C**: 1H NMR (400 MHz, $CDCl_3$) δ 8.44 (d, J = 4.4 Hz, 1H), 8.14 (br, 1H), 7.67 (td, J = 7.6, 1.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.30 – 7.25 (m, 3H), 7.23 – 7.19 (m, 3H), 7.16 (dd, J = 7.2, 4.8 Hz, 1H), 2.42 (s, 3H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.85, 164.39, 147.68, 140.65, 137.24, 135.59, 134.35, 132.86, 130.78, 129.90, 128.69, 128.53, 122.03, 121.87, 120.11, 119.62, 91.02, 88.68, 57.41, 27.66, 19.43; **HRMS** (EI-TOF) calcd for $C_{24}H_{21}ClN_2O$ (M^+): 388.1342, found: 388.1342.



2-methyl-6-((4-pentylphenyl)ethynyl)-N-(2-(pyridin-2-yl)propan-2-yl)benzamide
5h

Following **Condition C**: 1H NMR (400 MHz, $CDCl_3$) δ 8.43 (d, J = 4.4 Hz, 1H), 8.07 (br, 1H), 7.62 (td, J = 8.0, 1.6 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 7.2 Hz, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.23 (t, J = 7.6 Hz, 1H), 7.17 – 7.11 (m, 2H), 7.05 (d, J = 8.0 Hz, 2H), 2.55 (t, J = 7.6 Hz, 2H), 2.41 (s, 3H), 1.90 (s, 6H), 1.61 - 1.52 (m, 2H), 1.32 – 1.26 (m, 4H), 0.87 (t, J = 6.8 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.94, 164.40, 147.66, 143.46, 140.36, 137.10, 135.47, 131.53, 130.30, 129.91, 128.42, 128.39, 121.88, 120.58, 120.41, 119.60, 92.48, 87.01, 57.41, 35.92, 31.50,


30.95, 27.68, 22.58, 19.40, 14.09; **HRMS** (EI-TOF) calcd for C₂₉H₃₂N₂O (M⁺): 424.2515., found: 424.2514.



2-(dec-1-yn-1-yl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide **5i**

Following **Condition C**: ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, *J* = 4.0 Hz, 1H), 7.98 (br, 1H), 7.72 (td, *J* = 8.0, 1.6 Hz, 1H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.27 – 7.26 (m, 1H), 7.17 (t, *J* = 7.2 Hz, 2H), 7.11 (d, *J* = 7.2 Hz, 1H), 2.37 (s, 3H), 2.30 (t, *J* = 7.2 Hz, 2H), 1.91 (s, 6H), 1.51 – 1.44 (m, 2H), 1.27 – 1.21 (m, 10H), 0.86 (t, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.19, 164.54, 147.69, 140.48, 137.08, 135.30, 129.89, 129.65, 128.29, 121.89, 121.16, 119.57, 93.64, 78.66, 57.29, 31.94, 29.22, 29.20, 29.07, 28.69, 27.64, 22.74, 19.69, 19.40, 14.20; **HRMS** (ESI-TOF) calcd for C₂₆H₃₅N₂O (M+H)⁺: 391.2744, found: 391.2747.


2.4 Gram-scale Reaction



To an oven-dried 100 mL screw-capped vial was added substrate **1a** (6.0 mmol), **2a** (12.0 mmol), Ni(OTf)₂ (0.03 mmol), NaHCO₃ (12 mmol), DME (0.06 mmol) in *t*-BuCN (6 mL). The mixture was stirred for 36 h at 150 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by chromatography on silica gel using hexane/EtOAc as the eluent to afford the product **3a** (1.436 g, 57%) and **4a** (657.9 mg, 18%).


2.5 Mechanistic Investigation

Intramolecular Competition KIE



To an oven-dried 50 mL screw-capped vial was added substrate **1a** (0.4 mmol), **2a** (0.8 mmol), Ni(OTf)₂ (0.8 mg, 0.002 mmol), NaHCO₃ (67.2 mg, 0.8 mmol), DME (0.004 mmol) in *t*-BuCN (0.5 mL). The mixture was stirred for 4 h at 150 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The residue was purified by preparative TLC using hexane/EtOAc as the eluent to afford the product. The ratio of product **3a/d₄-3a** was analyzed by ¹H NMR.

Radical Scavenger Reactions





To an oven-dried 50 mL screw-capped vial was added substrate **1a** (0.4 mmol), **2a** (0.8 mmol), Ni(OTf)₂ (0.8 mg, 0.002 mmol), NaHCO₃ (67.2 mg, 0.8 mmol), additives (0.4 mmol), DME (0.004 mmol) in *t*-BuCN (0.5 mL). The mixture was stirred for 24 h at 150 °C under N₂ followed by cooling. The resulting mixture was filtered through a celite pad and concentrated in *vacuo*. The yield of product **3a** was analyzed by ¹H NMR.

3. References:



1. Y. Aihara, N. Chatani, *J. Am. Chem. Soc.* 2013, **135**, 5308.
2. F-J. Chen, G. Liao, X. Li, J. Wu, B-F. Shi, *Org. Lett.* **DOI:** 10.1021/ol5027156
3. X. Li, Y-H. Liu, Yan-Hua, W-J. Gu, B. Li, F-J. Chen, B-F. Shi, *Org. Lett.* 2014, **16**, 3904.

4. NMR Spectra



1f





1i





1n





1p





1u





1v





1ae





3a





4a





3b




3c






3d







3e









3f




3g





3h




CC(C)N(C#CC1=CC=C2C(=C1)OC3=CC=CC=C2O3)C(=O)c4ccc5c(c4)OC6=CC=CC=C6O5


Chemical structure of the TIPS-protected molecule, showing the TIPS group (tert-butyl dimethylsilyl) attached to the alkyne. The structure is labeled with chemical shifts: 8.514, 8.504, 8.348, 7.460, 7.440, and 7.900.







3l







3m







3n







30







3p







3q







3r







3s







3t







3u





3v







Chemical Structure of 10: Cc1ccc(cc1)C#CC2=NC3=CC=CC=C3N2C(=O)N


¹H NMR Data (CDCl₃):

Chemical Shift (ppm)	Integration
8.509, 8.498, 8.479	1.00
7.657, 7.653, 7.638, 7.634, 7.467, 7.447, 7.357, 7.190, 7.170, 7.149, 7.136, 7.132, 7.119	0.92, 0.03, 1.00, 1.01, 1.04
7.26 (CDCl ₃)	-
2.352	3.03
0.108, 0.099, 0.079	6.15, 21.06





4w







3x








4x








3y







4y







3z



4z





3aa




4aa






3ab







4ab









3ac





4ac





3ad





4ad





3ae





3af




4af






3ag







4ag









5a





5b





5c





5d





5e





5f



5g



5h



5i

